Transaction overview
Christian Follmann, Chief Operating Officer of Hercules Capital, Inc. (NASDAQ: HTGC), executed an insider purchase of 5,000 shares of the firm’s common stock on March 4, 2026. The trades took place at prices between $14.60 and $14.78, producing an average cost of $14.68 and totaling $73,400. At the time this report was prepared, HTGC shares were trading at $15.11, a modest appreciation relative to Follmann’s average purchase price. The stock remains down 17% year-to-date.
Post-transaction ownership
Following the acquisition, Follmann holds 150,135 shares directly and an additional 350 shares indirectly through a spouse.
Valuation and income profile
The company is identified with a market value of $2.74 billion and trades at a price-to-earnings ratio of 8.08. Hercules Capital offers a dividend yield of 12.44% and, according to InvestingPro, has paid dividends in each of the past 22 consecutive years.
Recent corporate developments
Hercules published preliminary fourth-quarter and full-year estimates, projecting net asset value (NAV) per share to fall in a range between $12.10 and $12.16 as of December 31, 2025, which the company describes as an increase from the prior quarter.
In a separate financing move, Hercules amended a loan agreement with Savara Inc. to make up to an additional $75 million available to Savara, contingent on FDA approval of an investigational therapy. That commitment is presented as part of Savara’s plan to secure roughly $150 million in non-dilutive capital intended to support its drug launch activities.
Analyst and short-seller activity
Piper Sandler adjusted its stance on Hercules Capital, downgrading the company from Overweight to Neutral. The firm cited Hercules’ exposure to the software sector and potential risks tied to AI-related disruptions as part of its rationale.
A short report published by Hunterbrook raised questions about how Hercules values its software-related loans and whether the dividend is sustainable. The report highlighted that 35% of Hercules’ loan portfolio is allocated to software debt. Hunterbrook disclosed that it holds a short position in Hercules Capital while being long a basket of comparable securities.
Snapshot
The insider purchase by the COO and the company’s published NAV uptick sit alongside materially different external views: a high-yield profile and long-term dividend track record on the one hand, and analyst downgrades plus short-seller criticism on the other. The company’s amended financing with Savara links Hercules to a contingent, approval-dependent funding commitment in the biopharma space.
Note: This article presents the reported transactions, valuation metrics, company disclosures and outside analyses without editorial opinion.